Lab

Lamprou Lab

About the lab

The Lamprou Lab offers an excellent environment for research with several laboratories that are fitted with modern equipment. Our research lab expertise is in Emerging Technologies for Drug Delivery Systems and Medical Devices & Implants. Examples of Emerging biopharmaceutical & pharmaceutical technologies include: 3D Printing & Bioprinting, Electrospinning, Microfluidics & Lab-on-a-chip, and BioMEMS. Our studies include: formulation, physicochemical characterization, computational modelling, ex vivo, in vivo & in vitro evaluation. PubMed-based algorithms placed us in the top 0.1% of scholars in the world writing about Printing, and in the top 5 labs in UK for research in microfluidics. For more info, please visit: https://www.lamproulab.com/

Featured projects (1)

Project
Manufacturing of drug delivery systems, medical devices, and implants using innovative 3D printing & bioprinting technologies; including in-house preparation of filaments by hot-melt extrusion (HME). Research led by the Lamprou Lab.

Featured research (123)

3D printing was invented thirty years ago. However, its application in healthcare became prominent only in recent years to provide solutions for drug delivery and clinical challenges, and is constantly evolving. This cost-efficient technique utilises biocompatible materials and is used to develop model implants to provide a greater understanding of human anatomy and diseases, and can be used for organ transplants, surgical planning and for the manufacturing of advanced drug delivery systems. In addition, 3D printed medical devices and implants can be customised for each patient to provide a more tailored treatment approach. The advantages and applications of 3D printing can be used to treat patients with different eye conditions, with advances in 3D bioprinting offering novel therapy applications in ophthalmology. The purpose of this review paper is to provide an in-depth understanding of the applications and advantages of 3D printing in treating different ocular conditions in the cornea, glaucoma, retina, lids and orbits.
Breast cancer is the second most common cancer worldwide, characterized by a high incidence and mortality rate. Despite the advances achieved in cancer management, improvements in the quality of life of breast cancer survivors are urgent. Moreover, view the heterogeneity that char-acterizes tumors and patients, focusing on individuality is fundamental. In this context, 3D printing (3DP) and 4D printing (4DP) techniques allow for a patient-center approach. At present, 3DP applications against breast cancer are focused on three main aspects: treatment, tissue re-generation, and recovery of the physical appearance. Scaffolds, drug-loaded implants, and prosthetics have been successfully manufactured; however, some challenges must be overcome to shift to clinical practice. The introduction of the fourth dimension has led to an increase in the degree of complexity and customization possibilities. However, 4DP is still in the early stages, thus research is needed to prove its feasibility in healthcare applications. This review article provides an overview of current approaches for breast cancer management, including standard treatments and breast reconstruction strategies. The benefits and limitations of 3DP and 4DP technologies are discussed, as well as their application in the fight against breast cancer. Future perspectives and challenges are outlined to encourage and promote AM technologies in re-al-world practice.
The utilisation of alginate polymers for wound healing is well explored; however, little attention is paid towards the optimisation of the manufacturing process, especially in regards to the final morphological and rheological properties that are imparted to the alginate matrix. This is important as it helps to establish a set of guidelines for the consistent fabrication of mechanically strong polymer wafers, which in the context of manufacturing and production contributes to the reduction in research and development time required. In this study, the order of application with respect to cross-linking and freeze-drying parameters have been investigated, which shown to result in distinct differences in terms of their overall morphology and mechanical strength. The application of freeze-drying before cross-linking results in the uniform distribution of cross-links throughout the alginate wafer, thereby producing a mechanically strong polymer wafer that retains the dehydrated matrices original thickness and architecture. Based on the observed data, freeze-drying prior to cross-linking facilitates the increased permeation and distribution of the cross-linker solution into the polymer matrix, thus resulting in the uniform distribution of ionic cross-links, which is necessary to produce a more mechanically superior polymer matrix.
Introduction: Sustainability within the pharmaceutical industry is becoming a focal point for many companies, to improve the longevity and social perception of the industry. Both additive manufacturing (AM) and microfluidics (MFs) are continuously progressing, so are far from their optimisation in terms of sustainability; hence it's the aim of this review to highlight potential gaps alongside their beneficial features. Discussed throughout this review also will be an in-depth discussion on the environmental, legal, economic, and social particulars relating to these emerging technologies. Areas covered: Additive manufacturing (AM) and microfluidics (MFs) are discussed in depth within this review, drawing from up-to-date literature relating to sustainability and circular economies. This applies to both technologies being utilised for therapeutic and analytical purposes within the pharmaceutical industry. Expert opinion: It is the role of emerging technologies to be at the forefront of promoting a sustainable message by delivering plausible environmental standards whilst maintaining efficacy and economic viability. AM processes are highly customisable, allowing for their optimisation in terms of sustainability, from reducing printing time to reducing material usage by removing supports. MFs too is supporting sustainability via reduced material wastage and providing a sustainable means for point of care analysis.
In the recent years we have encountered significant advances in the manufacturing processes for medicinal products and medical devices, particularly after the recent pandemic and the turmoil in the supply chain. Trends in these technological advances on diagnosis of diseases and therapeutic treatments, heavily relied on new technologies that can transform personalised healthcare into commercialisation.

Lab head

Dimitrios A Lamprou
Department
  • School of Pharmacy
About Dimitrios A Lamprou
  • Dimitrios, is the author of over 130 peer-reviewed publications and of over 350 conference abstracts, has over 130 Invited talks in institutions and conferences across the world, and has secure Funding in excess of £2.5M. Has been recognised as world leader in Printing, with PubMed-based algorithms placed him in the top 0.1% of scholars in the world writing about Printing in the last 10 years. Moreover, his research lab is listed in the top 5 labs in UK for research in microfluidics.

Members (6)

Essyrose Mathew
  • Queen's University Belfast
Edward Weaver
  • Queen's University Belfast
Aikaterini Dedeloudi
  • Queen's University Belfast
Meabh Doherty
  • Queen's University Belfast
Eman Jaradat
  • Queen's University Belfast
Eronildo Pinto Junior
  • University of Campinas
Francesca Corduas
Francesca Corduas
  • Not confirmed yet
Sofia Moroni
Sofia Moroni
  • Not confirmed yet
Colette O'Hagan
Colette O'Hagan
  • Not confirmed yet

Alumni (22)

David Mallinson
  • University of Strathclyde
Maria Lazaridou
  • Aristotle University of Thessaloniki
Giulia Pitzanti
  • Queen's University Belfast
Verónica Fernández-Luna García
  • Madrid Institute for Advanced Studies